Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stake Boosted by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 8.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,767,901 shares of the medical equipment provider's stock after acquiring an additional 140,531 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.89% of Zimmer Biomet worth $186,743,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ZBH. HB Wealth Management LLC boosted its stake in Zimmer Biomet by 5.9% in the fourth quarter. HB Wealth Management LLC now owns 4,302 shares of the medical equipment provider's stock valued at $455,000 after acquiring an additional 241 shares during the period. Ballentine Partners LLC boosted its stake in Zimmer Biomet by 18.6% in the fourth quarter. Ballentine Partners LLC now owns 4,571 shares of the medical equipment provider's stock valued at $483,000 after acquiring an additional 716 shares during the period. Nisa Investment Advisors LLC boosted its stake in Zimmer Biomet by 1.2% in the fourth quarter. Nisa Investment Advisors LLC now owns 63,099 shares of the medical equipment provider's stock valued at $6,680,000 after acquiring an additional 729 shares during the period. Dakota Wealth Management boosted its stake in Zimmer Biomet by 1.3% in the fourth quarter. Dakota Wealth Management now owns 9,620 shares of the medical equipment provider's stock valued at $1,016,000 after acquiring an additional 122 shares during the period. Finally, Brighton Jones LLC acquired a new position in Zimmer Biomet in the fourth quarter valued at approximately $204,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Price Performance

Shares of NYSE ZBH traded down $1.05 during trading on Wednesday, hitting $93.16. The company had a trading volume of 284,223 shares, compared to its average volume of 1,792,006. The company has a market cap of $18.43 billion, a P/E ratio of 20.92, a PEG ratio of 1.95 and a beta of 0.78. Zimmer Biomet Holdings, Inc. has a 52 week low of $89.92 and a 52 week high of $117.45. The business's 50-day moving average is $101.09 and its 200 day moving average is $105.13. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The company had revenue of $1.91 billion for the quarter, compared to analysts' expectations of $1.89 billion. During the same quarter in the prior year, the company earned $1.94 earnings per share. The firm's revenue was up 1.1% on a year-over-year basis. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares of the company's stock, valued at $915,379.20. The trade was a 14.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.70% of the company's stock.

Analyst Ratings Changes

A number of brokerages have commented on ZBH. Robert W. Baird decreased their target price on Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Royal Bank of Canada reduced their price objective on Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. Raymond James reduced their price objective on Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. Needham & Company LLC reiterated a "hold" rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Morgan Stanley reduced their price objective on Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Zimmer Biomet presently has an average rating of "Hold" and a consensus price target of $111.53.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.